Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma, director of the Mantle Cell Lymphoma Program of Excellence, and a professor in the Department of Stem Cell Transplantation and Cellular Therapy in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, to provide perspective on the evolution of ibrutinib’s (Imbruvica's) use in the management of mantle cell lymphoma (MCL) since its approval in 2013, as well as recent data from the 2021 ASH Annual Meeting and Exposition with the BTK inhibitor. 

For example, findings from the phase 2 WINDOW-2 trial were presented during the virtual meeting. The results demonstrated that chemotherapy-free induction with the combination of ibrutinib, rituximab (Rituxan), and venetoclax (Venclexta) induced deep and durable responses in younger patients with MCL, suggesting that patients with low-risk disease do not require chemotherapy. 

Wang also touched on several emerging areas of study in MCL, including novel BTK inhibitors beyond ibrutinib, antibody-drug conjugates, and CAR T-cell therapies.

In our exclusive interview, Wang discussed the clinical experience with ibrutinib in MCL, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.